The serum procalcitonin (PCT) concentration was measured at randomization and, in most patients, at intervals thereafter, and analysis suggested that the baseline PCT level appeared to be a possible predictor of antibiotic therapy being restarted and of the occurrence of the composite outcome measure.
The finding that baseline PCT levels were strongly predictive of both a perceived need for restarting antibiotics and the composite outcome of death and need for further antibiotics deserves further study. In contrast, a large randomized clinical trial, found that ongoing monitoring of the PCT level beyond the baseline value was not useful in the decision to escalate antibiotic therapy [1, 2] . Other data, however, indicate that PCT monitoring may be useful in assisting in the decision to discontinue antibiotic administration.
Consistent with the trial's purpose of being only a pilot and feasibility study, it was underpowered relative to its end points. Its results are nonetheless consistent with clinical experience, as well as with some clinical trial data. Studies dealing with presumed pneumonia in the ICU, as well as with the use of rapid diagnostic techniques to avoid the need for coverage of a specific pathogen, such as Staphylococcus aureus, also point the way toward shortened durations of empirical antibiotic therapy [3] [4] [5] [6] . These results also strongly support the implementation of the Centers for Disease Control and Prevention's recommendation for a formal -antibiotic time-out‖ after 48-72 hours of empirical therapy.
Entry into this study required, in addition to suspected but not proven infection, the presence of only 2 of the 4 SIRS criteria: a temperature of >38°C or <36°C, a heart rate of >90 beats/minute, a respiratory rate of >20 breaths/minute, and a white blood cell count of >12 000 cells/mm3 or <4000 cells/mm3. In addition, the patients entered into the study had median Acute Physiology and Chronic Health Evaluation II scores of only 13-14 and Sequential Organ Failure Assessment scores of 8-11. Thus, the applicability to patients with a greater severity of illness is uncertain. Also, most patients had undergone cardiothoracic surgery, so the applicability of these findings to other patient types is also uncertain.
The biggest drawback is, of course, the small sample size, although the population was appropriate for the purposes of the study. The investigators actively examined practical aspects of the trial, including barriers to patient acquisition, such as a reliance on ICU personnel for case referral. As a result, the full study, the results of which we all anxiously await, will have a better chance of providing definitive results.
